Senior Director, Qualified Person for Pharmacovigilance, Europe

Job description

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a highly qualified and experienced EU-QPPV to join our dynamic team. The EU-QPPV will report to the Head of Global Patient Safety (GPS) and is responsible for ensuring compliance with pharmacovigilance (PV) obligations under EU regulations and according to Good Pharmacovigilance Practices (GVP). The EU-QPPV maintains oversight of the Marketing Authorization Holder’s (MAH) global PV system and the safety p...